BMS Counting On Initial Combo Use For Glucovance To Supplant Glucophage

Bristol-Myers Squibb's Glucovance (metformin/glyburide) is emerging from FDA in time to give Bristol a half a year or more to transfer the market from its $1.9 bil. single-agent product Glucophage to the new combo.